

# Saundra S Buys

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9154144/publications.pdf>

Version: 2024-02-01

81  
papers

9,053  
citations

101384

36  
h-index

58464

82  
g-index

85  
all docs

85  
docs citations

85  
times ranked

12152  
citing authors

#	ARTICLE	IF	CITATIONS
1	Maternal and prenatal factors and age at thelarche in the LEGACY Girls Study cohort: implications for breast cancer risk. <i>International Journal of Epidemiology</i> , 2023, 52, 272-283.	0.9	1
2	Breast and Prostate Cancer Risks for Male <i>BRCA1</i> and <i>BRCA2</i> Pathogenic Variant Carriers Using Polygenic Risk Scores. <i>Journal of the National Cancer Institute</i> , 2022, 114, 109-122.	3.0	19
3	Cancer Risks Associated With <i>BRCA1</i> and <i>BRCA2</i> Pathogenic Variants. <i>Journal of Clinical Oncology</i> , 2022, 40, 1529-1541.	0.8	90
4	Polygenic risk modeling for prediction of epithelial ovarian cancer risk. <i>European Journal of Human Genetics</i> , 2022, 30, 349-362.	1.4	23
5	Common variants in breast cancer risk loci predispose to distinct tumor subtypes. <i>Breast Cancer Research</i> , 2022, 24, 2.	2.2	15
6	OUP accepted manuscript. <i>International Journal of Epidemiology</i> , 2022, , .	0.9	0
7	Weight is More Informative than Body Mass Index for Predicting Postmenopausal Breast Cancer Risk: Prospective Family Study Cohort (ProF-SC). <i>Cancer Prevention Research</i> , 2022, 15, 185-191.	0.7	4
8	Body Mass Index and Mammographic Density in a Multiracial and Multiethnic Population-Based Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, 31, 1313-1323.	1.1	3
9	21-gene recurrence score testing utilization among older women from different races: A population-based study. <i>Journal of Geriatric Oncology</i> , 2021, 12, 206-211.	0.5	4
10	Comparing 5-Year and Lifetime Risks of Breast Cancer Using the Prospective Family Study Cohort. <i>Journal of the National Cancer Institute</i> , 2021, 113, 785-791.	3.0	13
11	Patient Interactions With an Automated Conversational Agent Delivering Pretest Genetics Education: Descriptive Study. <i>Journal of Medical Internet Research</i> , 2021, 23, e29447.	2.1	11
12	A Phase 1 dose-escalation study of disulfiram and copper gluconate in patients with advanced solid tumors involving the liver using S-glutathionylation as a biomarker. <i>BMC Cancer</i> , 2021, 21, 510.	1.1	21
13	A competing risks model with binary time varying covariates for estimation of breast cancer risks in <i>BRCA1</i> families. <i>Statistical Methods in Medical Research</i> , 2021, 30, 2165-2183.	0.7	2
14	Association of germline genetic variants with breast cancer-specific survival in patient subgroups defined by clinic-pathological variables related to tumor biology and type of systemic treatment. <i>Breast Cancer Research</i> , 2021, 23, 86.	2.2	7
15	Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 77-102.	2.3	498
16	Recreational Physical Activity and Outcomes After Breast Cancer in Women at High Familial Risk. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkab090.	1.4	1
17	Association of Genomic Domains in <i>BRCA1</i> and <i>BRCA2</i> with Prostate Cancer Risk and Aggressiveness. <i>Cancer Research</i> , 2020, 80, 624-638.	0.4	39
18	Considerations When Using Breast Cancer Risk Models for Women with Negative <i>BRCA1/BRCA2</i> Mutation Results. <i>Journal of the National Cancer Institute</i> , 2020, 112, 418-422.	3.0	1

#	ARTICLE	IF	CITATIONS
19	Recreational Physical Activity Is Associated with Reduced Breast Cancer Risk in Adult Women at High Risk for Breast Cancer: A Cohort Study of Women Selected for Familial and Genetic Risk. <i>Cancer Research</i> , 2020, 80, 116-125.	0.4	37
20	Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. <i>Nature Genetics</i> , 2020, 52, 56-73.	9.4	120
21	Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants. <i>Genetics in Medicine</i> , 2020, 22, 1653-1666.	1.1	82
22	Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. <i>Nature Genetics</i> , 2020, 52, 572-581.	9.4	265
23	Characterization of the Cancer Spectrum in Men With Germline BRCA1 and BRCA2 Pathogenic Variants. <i>JAMA Oncology</i> , 2020, 6, 1218.	3.4	48
24	Alcohol Consumption, Cigarette Smoking, and Risk of Breast Cancer for BRCA1 and BRCA2 Mutation Carriers: Results from The BRCA1 and BRCA2 Cohort Consortium. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 368-378.	1.1	24
25	Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers. <i>Breast Cancer Research</i> , 2020, 22, 8.	2.2	41
26	Fiber intake and the risk of head and neck cancer in the prostate, lung, colorectal and ovarian (PLCO) cohort. <i>International Journal of Cancer</i> , 2019, 145, 2342-2348.	2.3	17
27	Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers. <i>British Journal of Cancer</i> , 2019, 121, 180-192.	2.9	19
28	Regular use of aspirin and other non-steroidal anti-inflammatory drugs and breast cancer risk for women at familial or genetic risk: a cohort study. <i>Breast Cancer Research</i> , 2019, 21, 52.	2.2	44
29	Population-based relative risks for specific family history constellations of breast cancer. <i>Cancer Causes and Control</i> , 2019, 30, 581-590.	0.8	7
30	Association of Prepubertal and Adolescent Androgen Concentrations With Timing of Breast Development and Family History of Breast Cancer. <i>JAMA Network Open</i> , 2019, 2, e190083.	2.8	7
31	10-year performance of four models of breast cancer risk: a validation study. <i>Lancet Oncology</i> , The, 2019, 20, 504-517.	5.1	116
32	Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization Study. <i>Journal of the National Cancer Institute</i> , 2019, 111, 350-364.	3.0	30
33	Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations. <i>Human Mutation</i> , 2018, 39, 593-620.	1.1	224
34	Breast cancer family history and allele-specific DNA methylation in the legacy girls study. <i>Epigenetics</i> , 2018, 13, 240-250.	1.3	10
35	Comparison of methods to assess onset of breast development in the LEGACY Girls Study: methodological considerations for studies of breast cancer. <i>Breast Cancer Research</i> , 2018, 20, 33.	2.2	9
36	The impact of folate intake on the risk of head and neck cancer in the prostate, lung, colorectal, and ovarian cancer screening trial (PLCO) cohort. <i>British Journal of Cancer</i> , 2018, 118, 299-306.	2.9	16

#	ARTICLE	IF	CITATIONS
37	Age-specific breast cancer risk by body mass index and familial risk: prospective family study cohort (ProF-SC). <i>Breast Cancer Research</i> , 2018, 20, 132.	2.2	51
38	Oral Contraceptive Use and Breast Cancer Risk: Retrospective and Prospective Analyses From a BRCA1 and BRCA2 Mutation Carrier Cohort Study. <i>JNCI Cancer Spectrum</i> , 2018, 2, pky023.	1.4	33
39	Breast cancer risk prediction using a polygenic risk score in the familial setting: a prospective study from the Breast Cancer Family Registry and kConFab. <i>Genetics in Medicine</i> , 2017, 19, 30-35.	1.1	53
40	Early Detection of Ovarian Cancer using the Risk of Ovarian Cancer Algorithm with Frequent CA125 Testing in Women at Increased Familial Risk – Combined Results from Two Screening Trials. <i>Clinical Cancer Research</i> , 2017, 23, 3628-3637.	3.2	99
41	A study of over 35,000 women with breast cancer tested with a 25-gene panel of hereditary cancer genes. <i>Cancer</i> , 2017, 123, 1721-1730.	2.0	303
42	A Phase I Study of Neoadjuvant Chemotherapy With Nab-Paclitaxel, Doxorubicin, and Cyclophosphamide in Patients With Stage II to III Breast Cancer. <i>Clinical Breast Cancer</i> , 2017, 17, 503-509.	1.1	7
43	Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 2402.	3.8	1,898
44	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. <i>Nature Genetics</i> , 2017, 49, 680-691.	9.4	356
45	Combating subclonal evolution of resistant cancer phenotypes. <i>Nature Communications</i> , 2017, 8, 1231.	5.8	124
46	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. <i>Nature Genetics</i> , 2017, 49, 1767-1778.	9.4	289
47	Non-invasive optical spectroscopic monitoring of breast development during puberty. <i>Breast Cancer Research</i> , 2017, 19, 12.	2.2	14
48	Pubertal development in girls by breast cancer family history: the LEGACY girls cohort. <i>Breast Cancer Research</i> , 2017, 19, 69.	2.2	18
49	Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3. <i>Breast Cancer Research and Treatment</i> , 2017, 161, 117-134.	1.1	18
50	Do cancer survivors develop healthier lifestyle behaviors than the cancer-free population in the PLCO study?. <i>Journal of Cancer Survivorship</i> , 2017, 11, 233-245.	1.5	18
51	Multigene and Drug Interaction Approach for Tamoxifen Metabolite Patterns Reveals Possible Involvement of CYP2C9, CYP2C19, and ABCB1. <i>Journal of Clinical Pharmacology</i> , 2016, 56, 1570-1581.	1.0	17
52	Response: Table 1.. <i>Journal of the National Cancer Institute</i> , 2016, 108, djw173.	3.0	2
53	Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus. <i>Breast Cancer Research</i> , 2016, 18, 64.	2.2	31
54	Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. <i>Breast Cancer Research</i> , 2016, 18, 15.	2.2	88

#	ARTICLE	IF	CITATIONS
55	An international survey of surveillance schemes for unaffected BRCA1 and BRCA2 mutation carriers. <i>Breast Cancer Research and Treatment</i> , 2016, 157, 319-327.	1.1	26
56	Extended mortality results for ovarian cancer screening in the PLCO trial with median 15 years follow-up. <i>Gynecologic Oncology</i> , 2016, 143, 270-275.	0.6	111
57	Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women. <i>Breast Cancer Research</i> , 2016, 18, 112.	2.2	42
58	Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer. <i>Nature Communications</i> , 2016, 7, 11375.	5.8	93
59	Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus. <i>Nature Communications</i> , 2016, 7, 12675.	5.8	78
60	Integrative analyses reveal signaling pathways underlying familial breast cancer susceptibility. <i>Molecular Systems Biology</i> , 2016, 12, 860.	3.2	14
61	Evaluation of the relevance and access of EHR-based variables to support personalized medicine in breast cancer. <i>Cogent Medicine</i> , 2016, 3, 1234661.	0.7	1
62	Cohort Profile: The Breast Cancer Prospective Family Study Cohort (ProF-SC). <i>International Journal of Epidemiology</i> , 2016, 45, 683-692.	0.9	48
63	Comparison of Clinical, Maternal, and Self Pubertal Assessments: Implications for Health Studies. <i>Pediatrics</i> , 2016, 138, .	1.0	36
64	Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. <i>Nature Genetics</i> , 2016, 48, 374-386.	9.4	125
65	Breast Cancer Risk Perceptions among Relatives of Women with Uninformative Negative <i>BRCA1/2</i> Test Results: The Moderating Effect of the Amount of Shared Information. <i>Journal of Genetic Counseling</i> , 2016, 25, 258-269.	0.9	21
66	No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. <i>Gynecologic Oncology</i> , 2016, 141, 386-401.	0.6	18
67	An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in <i>BRCA2</i> mutation carriers. <i>Breast Cancer Research</i> , 2015, 17, 61.	2.2	26
68	31: Impact of Multiple CYP Variants on Tamoxifen Metabolite Concentrations. <i>American Journal of Clinical Pathology</i> , 2015, 143, A015-A015.	0.4	0
69	Coffee, tea, caffeine intake, and the risk of cancer in the PLCO cohort. <i>British Journal of Cancer</i> , 2015, 113, 809-816.	2.9	99
70	Identification of six new susceptibility loci for invasive epithelial ovarian cancer. <i>Nature Genetics</i> , 2015, 47, 164-171.	9.4	221
71	Association of Type and Location of <i>BRCA1</i> and <i>BRCA2</i> Mutations With Risk of Breast and Ovarian Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 1347.	3.8	390
72	Candidate Genetic Modifiers for Breast and Ovarian Cancer Risk in <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 308-316.	1.1	22

#	ARTICLE	IF	CITATIONS
73	Expanding Access to BRCA1/2 Genetic Counseling with Telephone Delivery: A Cluster Randomized Trial. <i>Journal of the National Cancer Institute</i> , 2014, 106, dju328-dju328.	3.0	105
74	DNA Glycosylases Involved in Base Excision Repair May Be Associated with Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. <i>PLoS Genetics</i> , 2014, 10, e1004256.	1.5	47
75	Rare Mutations in <i>RINT1</i> Predispose Carriers to Breast and Lynch Syndrome—“Spectrum Cancers. <i>Cancer Discovery</i> , 2014, 4, 804-815.	7.7	44
76	Breast-Cancer Risk in Families with Mutations in <i>PALB2</i> . <i>New England Journal of Medicine</i> , 2014, 371, 497-506.	13.9	745
77	Analysis of Serial Ovarian Volume Measurements and Incidence of Ovarian Cancer: Implications for Pathogenesis. <i>Journal of the National Cancer Institute</i> , 2014, 106, .	3.0	16
78	Effect of Screening on Ovarian Cancer Mortality. <i>JAMA - Journal of the American Medical Association</i> , 2011, 305, 2295.	3.8	1,080
79	The Breast Cancer Family Registry: an infrastructure for cooperative multinational, interdisciplinary and translational studies of the genetic epidemiology of breast cancer. <i>Breast Cancer Research</i> , 2004, 6, R375-89.	2.2	255
80	The spectrum of apoptotic defects and clinical manifestations, including systemic lupus erythematosus, in humans with CD95 (Fas/APO-1) mutations. <i>Arthritis and Rheumatism</i> , 1999, 42, 1833-1842.	6.7	90
81	Effect of volume and pH on surface receptor number in macrophages. <i>Journal of Cellular Physiology</i> , 1989, 140, 371-378.	2.0	4